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Calmodulin (CaM) is a small cytoplasmic Ca2+ binding protein 
that regulates numerous cellular activities. CaM may exert its 
action through a direct interaction with its target proteins or indi-
rectly by regulating the activity of Ca2+/CaM-dependent protein 
kinase, and CaM stimulated protein phosphatase (calcineurin) (1, 
2). In cardiac muscle, CaM modulates, directly or indirectly, the 
activity of proteins that play a key role in the release and subse-
quent sequestration of cytosolic Ca2+ back into the sarcoplasmic 
reticulum (SR). Three target proteins are the voltage- and dihydro-
pyridine-sensitive surface membrane L-type Ca2+ channel (Cav1.2) 
(3, 4), cardiac muscle cell Ca2+ release channel ryanodine receptor 2 
(RyR2) (2, 5), and SR Ca2+ ATPase–associated (SERCA2a-associ-
ated) protein phospholamban (6). During an action potential, the 
entry of Ca2+ through the L-type Ca2+ channel triggers the massive 
release of Ca2+ from the SR by opening Ca2+-gated RyR2 ion chan-
nels. The released Ca2+ initiates muscle contraction. The subse-
quent sequestration of released Ca2+ back into the SR by SERCA2a 
leads to muscle relaxation.
The cardiac Ca2+ release channel is comprised of four 560-kDa 
RyR2 subunits, four 12.6-kDa FK506-binding protein subunits, 
and various associated proteins that include Ca2+/CaM-depen-
dent protein kinase II (CaMKII), calcineurin, and CaM (5, 7–9). A 
bimodal dependence of RyR2 activity on the physiological activa-
tor Ca2+ suggests the presence of high-affinity (micromolar) acti-
vating and low-affinity (millimolar) inhibitory Ca2+ binding sites. 
CaM inhibits Ca2+-gated RyR2 activity by binding to a single site 
highly conserved among the RyRs (10). In single-channel mea-
surements, CaM lowered RyR2 channel open probability from low 
micromolar to submicromolar Ca2+ concentrations by decreasing 
the number of channel events and increasing the duration of close 
times (11). These data have suggested that CaM provides a comple-
mentary mechanism for regulating SR Ca2+ release in addition to 
the regulation of RyR2 by Ca2+. The physiological importance of 
regulation of RyR2 by CaM, however, is not well understood.
To explore the role of CaM regulation of RyR2 in vivo, we gen-
erated a mouse model with 3 amino acid replacements (RyR2-
W3587A/L3591D/F3603A [RyR2ADA]) in the Ryr2 gene that was 
hypothesized to impair CaM regulation of RyR2 in vivo. We 
assessed the effects of impaired CaM regulation of RyR2 on ani-
mal survival, cardiac function, SR Ca2+ release and sequestration, 
and expression of genes associated with cardiac hypertrophy. The 
results show that impaired CaM regulation of RyR2 is associated 
with an abnormal SR Ca2+ release and altered gene regulation, 
which lead to cardiac hypertrophy and early death of the homozy-
gous mutant (Ryr2ADA/ADA) mice.
Results
CaM regulates multiple cellular functions. We have previously 
shown that deletion of amino acid residues 3583–3603 eliminated 
CaM binding and CaM regulation of the cardiac ryanodine recep-
tor ion channel (RyR2) in vitro (10). In the present study, we gen-
erated a mouse with 3 amino acid substitutions (RyR2ADA) in the 
CaM-binding domain to attenuate CaM regulation of RyR2 by 
gene targeting (Supplemental Figures 1–3; supplemental material 
available online with this article; doi:10.1172/JCI29515DS1).
RyR2ADA is associated with cardiac hypertrophy and early death of homo-
zygous mutant mice. Homozygous expression of RyR2ADA resulted in 
larger hearts compared with WT at day 10 (Figure 1A). Body weight 
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was reduced by about 10% in 7- and 10-day-old homozygous mutant 
mice compared with that of WT mice, without a noticeable change 
in 1-day-old mice (Figure 1B). One-day-old homozygous mutant 
mice exhibited 1.2 times higher ratio of heart weight to body weight 
compared with WT mice, which became progressively higher ratios 
of 1.7 and 2.2 for 7- and 10-day-old mice, respectively (Figure 1C). 
There was a small but significant difference between heart weight/
body weight ratios of heterozygous (Ryr2+/ADA) and WT mice at day 
1 but no difference at days 7 and 10 (Figure 1C). Homozygous mice 
at day 10 displayed no obvious symptoms in other tissues. Lung/
body and liver/body weight ratios were indistinguishable among 
the 3 genotypes at day 10, and histological analyses of the 2 tissues 
showed no discernible abnormalities (not shown).
The mutations did not cause prenatal death, as heterozygous 
matings produced 3 genotypes of neonates close to the expected 
Mendelian ratio (WT, 25% [n = 274]; heterozygous, 53% [n = 586]; 
homozygous, 22% [n = 245]). However, homozygous mutant mice 
started to die at day 9 or 10 (10 of 117 mice that lived longer than 7 
days). Thus, a majority of mice were analyzed at day 10 and earlier. 
Of 14 homozygous mutant mice that survived to 10 days, none 
survived beyond 16 days (Figure 1D). Heterozygous mice were 
indistinguishable from WT in lifespan. Taken together, the results 
indicated that homozygous mutant mice developed cardiac hyper-
trophy by at least 1 day after birth.
Histological examination supported the development of cardiac 
hypertrophy in homozygous mice. Inspection of hearts of 10-day-
old Ryr2ADA/ADA mice suggested increase in cross-sectional area 
of left ventricular cardiomyocytes (Figure 2, A and B). A less pro-
nounced increase in cross-sectional area was observed in septal and 
right ventricular myocytes. Heterozygous mice exhibited a small 
but significant decrease in cross-sectional area of septal and left 
ventricular cardiomyocytes. Masson trichrome staining revealed 
the presence of collagen deposits, which suggested a modest degree 
of fibrosis in left ventricular tissue of 10-day-old homozygous mice 
(Figure 2C). An abundant accumulation of collagen was observed 
in papillary muscle of 10-day-old homozygous mice (Figure 2D).
The above results suggest that an impaired CaM regulation 
of RyR2 leads to severe left ventricular hypertrophy. To confirm 
this, we determined the levels of expression of 3 genes associated 
with cardiac hypertrophy (12–14). Quantitative RT-PCR showed 
that the mRNA levels of β-myosin heavy chain (β-MHC), atrial 
natriuretic peptide, and brain natriuretic peptide (BNP) were 
upregulated in left ventricle of 7- and 10-day homozygous hearts 
(Figure 3). A significant upregulation of β-MHC and BNP was 
already observed in hearts of 1-day-old homozygous mice, which 
suggests that cardiac remodeling starts before 1 day of age, in 
agreement with an increase of heart weight/body weight ratio at 1 
day of age (Figure 1C).
Echocardiography and electrocardiography of wild type and mutant mice. 
To determine whether the RyR2ADA mutation altered cardiac func-
tion, we performed echocardiography and electrocardiography on 
conscious animals. The heart rate of 7- and 10-day-old Ryr2ADA/ADA 
mice was significantly slower than that of WT mice (431 ± 22 
versus 599 ± 16, and 461 ± 19 versus 598 ± 21 bpm, respectively, 
Table 1). Both left ventricular end-diastolic and -systolic dimen-
sions were significantly larger in homozygous mouse hearts than 
in WT mouse hearts (Figure 4A). Significantly reduced fractional 
shortening (P < 0.001) obtained from these 2 parameters indi-
cated progressively exacerbating cardiac function in 7- and 10-day 
homozygous hearts compared with WT hearts. Interventricular 
septum thickness was decreased in homozygous hearts, whereas 
left ventricular posterior wall thickness of homozygous hearts did 
Figure 1
Body weights, heart weight to body weight ratios, and survival of WT and mutant mice. (A) H&E-stained heart sections of 10-day-old WT and 
mutant mice. Scale bar: 1 mm. (B) Body weights and (C) heart weight to body weight ratios of WT and mutant mice. Data are mean ± SEM 
of 25–150 (1- to 10-day-old) or 11–14 (13-week-old) mice. *P < 0.05, #P < 0.0001 compared with WT. (D) Survival of WT and mutant mice 
after 10 days. Data for 10 WT, 15 heterozygous (HET), and 14 homozygous (HOM) mice are shown. The mean survival of homozygous mice 
was 13.6 ± 0.4 days.
research article
1346	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 117   Number 5   May 2007
not substantially differ from that of WT hearts (Table 1). None of 
left ventricular parameters of heterozygous mice were significant-
ly different from those of WT mice. Taken together, these results 
indicate that by 7 and 10 days of age, cardiac hypertrophy is associ-
ated with ventricular dysfunction of Ryr2ADA/ADA mice.
Representative electrocardiogram recordings of 10-day-old 
WT and homozygous mutant mice are shown in Figure 4B. Elec-
trocardiogram of homozygous mice showed atypical recordings 
and significantly slower heart rates compared with WT mice 
(457 ± 21 versus 590 ± 25 bpm; n = 6–7; P < 0.05), consistent with 
results of echocardiography.
CaM binding and regulation of RyR2 isolated from hearts of WT and 
mutant mice. CaM binding to solubilized RyR2 was analyzed by 
CaM-Sepharose pull-down and Western blot. Figure 5A shows that 
RyR2s isolated from WT and heterozygous hearts bound to CaM 
in the presence of 900 μM Ca2+. Exogenously added CaM (2 μM) 
greatly reduced the amount of bound RyR2, which confirmed the 
specificity of CaM binding to RyR2. In agreement with results of 
recombinant RyR2s expressed in HEK293 cells (Supplemental Fig-
ure 1), no specific CaM binding to RyR2 from homozygous hearts 
was observed. The efficacy of the RyR2ADA mutation in eliminat-
ing CaM regulation of RyR2 in cardiomyocytes was probed, using 
the RyR-specific probe ryanodine (15). In initial experiments, we 
determined maximal [3H]ryanodine binding capacity (Bmax) val-
ues of [3H]ryanodine binding in crude membrane fractions rep-
resentative of the total particulate matter (Table 2). Homozygous 
expression of RyR2ADA in hearts of 7- and 10-day-old, but not 
1-day-old, mice was associated with significantly reduced Bmax 
values of [3H]ryanodine binding, which suggests a lower RyR2 
protein concentration in 7- and 10-day Ryr2ADA/ADA hearts as com-
pared with Ryr2+/+ hearts (Table 2). A small but significant decrease 
(P < 0.05) in Bmax of [3H]ryanodine binding was also observed with 
10-day Ryr2+/ADA compared with WT hearts. However, as shown in 
Figure 5B, in the absence of CaM, the ADA mutation in RyR2 did 
not significantly alter the Ca2+ dependence of [3H]ryanodine bind-
ing to membranes isolated from hearts of 7-day-old mice. Figure 
5C shows that at 1.2 μM free Ca2+, addition of physiological (50–75 
nM; refs. 16, 17) concentration of CaM decreased [3H]ryanodine 
binding to membranes prepared from Ryr2+/+ and Ryr2+/ADA 
hearts, whereas only a small but significant (P < 0.05) decrease of 
Figure 2
Histological analysis of WT and homozygous mice. (A) 
Heart sections were stained with TRITC-conjugated 
wheat germ agglutinin to outline cell borders (green 
pseudocolor). Left ventricles of 10-day-old mice are 
shown. (B) Cross-sectional areas of cardiomyocytes 
(n = 250 for each genotype) from 5 different hearts were 
measured. *P < 0.01 compared with WT. Cells were 
selected randomly by a person who was blinded to gen-
otype. In each of 5 heart cross-sections, areas of left 
ventricle in homozygous mice were significantly larger 
that those in WT mice. (C and D) Masson trichrome—
stained left ventricle muscle (C) and papillary muscle (D) 
of 10-day-old mice are shown. Scale bars: 50 μm.
Figure 3
Quantitative RT-PCR analysis of marker genes for car-
diac hypertrophy. RT-PCR analyses were performed 
using total RNA isolated from left and right ventricles 
of 1-day-old mice and left ventricle of 7- and 10-day-
old mice. RNA transcription levels were normalized to 
those of WT for each of 3 genes. ANP, atrial natriuretic 
peptide; BNP, brain natriuretic peptide; β-MHC, β-myosin 
heavy chain. Data are the mean ± SEM of 8–10 samples. 
*P < 0.05, #P < 0.001 compared with WT.
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[3H]ryanodine binding was measured with Ryr2ADA/ADA membranes 
in presence of high CaM concentration (800 nM).
The effects of the ADA mutation on interaction between RyR2 and 
CaM were also examined in single-channel measurements. Mem-
branes isolated from the hearts of WT (left panels) and homozygous 
(right panels) mice were fused with lipid bilayer. There was no sig-
nificant difference in baseline (0.1 μM cytoplasmic Ca2+) open-chan-
nel probability between WT and homozygous mutant channels (not 
shown). The regulatory effects of CaM, as reflected by changes in RyR 
channel open probabilities, were then determined in presence of 0.4 
or 2 μM free cis (cytosolic) Ca2+ by adding exogenous CaM to the cis 
(cytosolic) side of the bilayer. In good agreement with single-chan-
nel measurements of recombinant RyR2s (Supplemental Figure 2), 
addition of 1 μM CaM inhibited both WT and homozygous mutant 
channels at 0.4 μM Ca2+, whereas 50 nM CaM inhibited only WT 
channels significantly (P < 0.05; Figure 6A). At 2 μM Ca2+, 50 nM and 
1 μM CaM did not affect activity of homozygous mutant channels, 
whereas the open probability of WT channels decreased to 56 ± 4% 
and 51 ± 7%, respectively (Figure 6B). In reasonable agreement with 
[3H]ryanodine binding measurements (Figure 5C), a majority RyR2 
channels (9 of 10) from heterozygous hearts were inhibited at 2 μM 
Ca2+ by 50 nM CaM and 1 μM 
CaM. The extent of inhibition 
was comparable to that of WT-
RyR2 channels (not shown). 
Kinetic analysis showed no 
significant differences between 
CaM-depleted WT and mutant 
channels with regard to num-
ber of channel events and mean 
open and close times (Figure 6). 
Taken together, [3H]ryanodine 
binding and single-channel 
measurements suggest that 
substitution of 3 amino acid 
residues in RyR2 CaM regula-
tory domain reduces CaM inhi-
bition in homozygous hearts 
without inducing major protein 
conformational changes. More-
over, maintenance of CaM inhibition by the majority of heterozygous 
channels was consistent with our finding that Ryr2+/ADA mice showed 
no major signs of cardiac hypertrophy.
Ca2+ transients in spontaneously beating cardiomyocytes isolated from 
hearts of WT and mutant mice. The functional effects of the RyR2ADA 
mutation were also probed by measuring Ca2+ transients in intact 
cultured cardiomyocytes, using fluo-4 and confocal laser scanning 
microscopy. We could distinguish between 2 types of spontaneous-
ly beating cardiomyocytes. In 1 group of cardiomyocytes, cytosolic 
Ca2+ concentration was rapidly increased, then maintained for 
varying times before declining to resting levels (Figure 7, A and B). 
Mean data showed that mean duration of elevated Ca2+ level was 
about 10 times greater in homozygous cardiomyocytes than in WT 
cardiomyocytes (bars in Figure 7, A, B, and D). In heterozygous 
cardiomyocytes, the plateau phase of the Ca2+ transient was also 
increased, but to a much smaller extent than in homozygous car-
diomyocytes (Figure 7D). Differences were also observed in the 
time of Ca2+ removal. The time constant for decline to resting Ca2+ 
levels showed a significant increase in homozygous cardiomyo-
cytes and a smaller (insignificant) increase in heterozygous myo-
cytes as compared with WT myocytes (Figure 7E).
Table 1
Echocardiography in WT and mutant mice
	 7	days	old	 10	days	old
Parameters	 WT	 HET	 HOM	 WT	 HET	 HOM
HR (bpm) 599 ± 16 569 ± 11 431 ± 22A 598 ± 21 585 ± 10 461 ± 19A
LVEDD (mm) 1.57 ± 0.09 1.65 ± 0.05 2.66 ± 0.16A 1.83 ± 0.15 1.91 ± 0.10 3.19 ± 0.23A
LVESD (mm) 0.67 ± 0.07 0.81 ± 0.04 2.15 ± 0.17A 0.73 ± 0.10 0.82 ± 0.08 2.80 ± 0.29A
FS (%) 57.6 ± 3.0 50.9 ± 2.4 19.1 ± 3.1A 61.3 ± 3.0 57.3 ± 2.9 13.0 ± 3.6A
IVSD (mm) 0.74 ± 0.05 0.70 ± 0.06 0.65 ± 0.07 0.99 ± 0.06 0.91 ± 0.08 0.79 ± 0.07
IVSS (mm) 1.10 ± 0.07 1.08 ± 0.04 0.83 ± 0.05B 1.33 ± 0.07 1.27 ± 0.08 0.93 ± 0.03B
LVPWD (mm) 0.65 ± 0.08 0.61 ± 0.05 0.76 ± 0.08 0.68 ± 0.07 0.76 ± 0.07 0.96 ± 0.08
LVPWS (mm) 1.02 ± 0.08 0.90 ± 0.03 0.87 ± 0.07 1.08 ± 0.08 1.20 ± 0.05 1.01 ± 0.07
FS, fractional shortening ([LVEDD – LVESD]/LVEDD); HET; heterozygous; HOM, homozygous; HR, heart rate; 
IVSD, interventricular septum diastolic thickness; IVSS, interventricular septum systolic thickness; LVEDD, left 
ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVPWD, left ventricular pos-
terior wall diastolic thickness; LVPWS, left ventricular posterior wall systolic thickness. Data are mean ± SEM of 8 
(7-day-old) or 5–6 (10-day-old) mice for each group. AP < 0.001, BP < 0.01 compared with WT.
Figure 4
Echocardiograms and electrocardiograms 
of WT and mutant mice. (A) Representa-
tive M-mode echocardiograms of 7-day-old 
Ryr2+/+ and Ryr2ADA/ADA mice. Left ventricu-
lar end-diastolic (right arrows) and end-sys-
tolic (left arrows) dimensions are indicated. 
(B) Representative electrocardiograms of 
10-day-old WT and homozygous mice.
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A second group of myocytes displayed repeated periods of incom-
plete Ca2+ removal and Ca2+ release before declining to the resting 
level (Figure 7C). This behavior was primarily observed in homozy-
gous and heterozygous myocytes (13 of 27 and 8 of 23, respectively, 
versus 4 of 30 for WT). Mean data showed that the number of rap-
idly occurring, incomplete Ca2+ removal and Ca2+ release events was 
higher in homozygous cardiomyocytes (10.5 ± 2.2 repeats, n = 13) 
than in heterozygous (4.1 ± 0.7, n = 8) or WT (2.0 ± 0.0, n = 4) car-
diomyocytes. The duration of the plateau (Figure 7, A and B) and 
number of repetitive Ca2+ release events (Figure 7C) were indepen-
dent of culture days of cardiomyocytes.
Additional experiments with the 3 genotypes using the fluores-
cent Ca2+ indicator Fura-2 showed no significant differences in 
the resting cytosolic Ca2+ levels of spontaneously beating cardio-
myocytes (Figure 7F). Moreover, caffeine-induced Ca2+ release was 
not significantly different, as reflected by the ratio of peak minus 
baseline fluo-4 fluorescence to baseline fluorescence (Figure 7G), 
which suggested a similar SR Ca2+ content. Taken together, the 
data then suggest that an impaired CaM regulation of RyR2 alters 
cellular SR Ca2+ release and cytosolic Ca2+ removal.
To determine whether the reduced rates of cytosolic Ca2+ remov-
al in cardiomyocytes expressing the RyR2ADA mutation are associ-
ated with decreased SERCA2a activity in intact hearts, we mea-
sured uptake rates by membrane fractions isolated from 1-, 7-, 
and 10-day hearts of the radioisotope 45Ca2+. At day 1 and day 7, a 
25%–40% (not significant) decrease in the 45Ca2+ uptake rates was 
measured in membrane fractions isolated from heterozygous and 
homozygous hearts as compared with hearts expressing WT-RyR2 
(Table 2). At day 10, the 45Ca2+ uptake rates of membranes isolated 
from homozygous hearts were significantly lower than those from 
WT hearts (12.3 ± 1.6 versus 4.9 ± 1.4 nmol/mg protein/min; Table 
2). We conclude that, in the hearts of 10-day-old mice, the RyR2ADA 
mutation is associated with reduced SERCA2a activity and thereby 
may contribute to reduced rate of cytosolic Ca2+ sequestration in 
cultured mutant cardiomyocytes.
Activities of signaling molecules and CaM concentrations in WT and 
mutant hearts. We examined whether lack of CaM binding to RyR2ADA 
increased the pool of CaM available for binding to CaM-dependent 
kinases and phosphatases, leading to their activation in homozy-
gous mice. However, no increase in CaMKII activity (99 ± 12% [n = 3] 
of WT activity) was observed in 1-day-old homozygous mice, which 
already showed a hypertrophic response. Furthermore, amounts 
of CaM maximally bound to RyR2 (1.5–2.0 pmol/mg protein, or 
0.3–0.4 μM CaM) represent only a small fraction of total CaM. Total 
CaM concentration in hearts of WT (9.1 ± 0.6 μM) were slightly (but 
not significantly) higher than in heterozygous (7.4 ± 1.1 μM) and 
homozygous (8.2 ± 0.7 μM) 10-day-old mice (n = 4), as determined 
by quantitative immunoblot analysis.
We also considered the possibility that impaired CaM regula-
tion of RyR2 is associated with an aberrant activity of signaling 
molecules implicated in cardiac hypertrophy. In pathological car-
diac hypertrophy, phosphorylation of class II histone deacetylases 
(HDACs) by CaMKII, protein kinases C and D, and other yet to 
be identified kinases results in derepression of myocyte enhancer 
factor-2 (MEF2) and other transcription factors (18, 19). We used 
GST-HDAC4 fusion proteins (amino acids 419–670) to test for an 
Figure 5
CaM binding and regulation of RyR2 from hearts of WT and mutant 
mice. (A) Western blots of RyR2 bound to CaM-Sepharose beads. 
Input RyR2s (left) and RyR2s bound to CaM-Sepharose in the 
absence (–) or presence (+) of 2 μM CaM (right). (B and C) Specific 
[3H]ryanodine binding to crude membrane fractions from hearts of 
7-day-old and 10-day-old WT, heterozygous, and homozygous mice 
was determined as described in Supplemental Methods. (B) Ca2+ depen-
dence of [3H]ryanodine binding in absence of CaM. (C) [3H]ryanodine 
binding as a function of CaM concentration at 1.2 μM Ca2+. Data are the 
mean ± SEM of 4–6 experiments. *P < 0.05, #P < 0.01 compared with 
control (no CaM added), as determined by Student’s t test.
Table 2
Biochemical properties of WT and mutant hearts
	 Bmax	of	[3H]ryanodine	binding	(pmol/mg	protein)	 45Ca2+	uptake	(nmol/mg	protein/min)
Age	(d)	 WT	 HET	 HOM	 WT	 HET	 HOM
1 0.41 ± 0.08 (5) 0.38 ± 0.05 (8) 0.31 ± 0.08 (5) 8.0 ± 2.0 (3) 5.9 ± 0.6 (7) 6.0 ± 0.6 (4)
7 0.48 ± 0.07 (13) 0.40 ± 0.05 (16) 0.19 ± 0.04 (11)A 10.2 ± 2.1 (6) 7.5 ± 1.9 (6) 6.2 ± 1.1 (6)
10 0.43 ± 0.04 (12) 0.32 ± 0.04 (17)B 0.13 ± 0.02 (15)C 12.3 ± 1.6 (5) 11.9 ± 1.2 (6) 4.9 ± 1.4 (5)A
91 0.90 ± 0.06 (4) 0.78 ± 0.03 (4) – 12.8 ± 0.8 (4) 13.7 ± 2.2 (4) –
Data are the mean ± SEM of number of experiments shown in parentheses. Bmax, maximal binding capacity; –, no surviving mice at 91 days. AP < 0.01,  
BP < 0.05, CP < 0.001 compared with WT. 
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upregulation of kinases implicated in class II HDAC phosphoryla-
tion and gene remodeling. A significantly increased phosphory-
lation of HDAC4 by lysates from homozygous hearts at day 1 as 
compared with WT hearts was observed (Figure 8, A and B). R601F 
mutant HDAC4, which lacks CaMKII docking site (19), was also 
phosphorylated to a greater extent by lysates from homozygous 
hearts than by lysates from WT hearts. In complementary stud-
ies, autocamtide-2 related inhibitory peptide, a specific inhibitor 
of CaMKII, did not substantially reduce HDAC phosphorylation 
(data not shown). By comparison, phosphorylation of HDAC4 was 
reduced to background levels by the nonspecific kinase inhibitor 
staurosporin. The results are consistent with our finding that 
heart homogenates of 1-day-old WT and homozygous mice had 
comparable CaMKII activities and suggest that kinase(s) other 
than CaMKII enhanced HDAC4 phosphorylation. In agreement 
with increased phosphorylation of HDAC4, MEF2 activities were 
upregulated in nuclear fractions from homozygous hearts (Figure 
8C), which suggests a derepression of class II HDAC target genes 
that contribute to cardiac hypertrophy and early death of the 
homozygous mutant (Ryr2ADA/ADA) mice.
We also tested the possibility that an aberrant SR Ca2+ release 
increased the activity of calcineurin, a Ca2+/CaM-activated serine/
threonine phosphatase that through dephosphorylation of nuclear 
factor of activated T cell (NFAT) transcriptionally regulates signal-
ing pathways implicated in pathological cardiac hypertrophy (20). 
Because traditional enzyme assays are technically and theo-
retically difficult (21), we tested for an enhanced calcineurin 
activity in the hearts of homozygous mice by determining 
the mRNA levels of myocyte-enriched calcineurin-interact-
ing protein 1 (MCIP1) by quantitative RT-PCR. As part of 
a compensatory response to an increased calcineurin activ-
ity, the protein levels of MCIP1 are upregulated in hypertro-
phic hearts (22). We found that the mRNA level of MCIP1 
was significantly increased in homozygous hearts at day 7 
(148 ± 15%; n = 10) and day 10 (201 ± 25%; n = 19), but not 
at day 1 (79 ± 7%; n = 10) compared with WT. It is therefore 
likely that the calcineurin/NFAT signaling pathway also has 
a role in gene remodeling in homozygous hearts.
Discussion
Ca2+ and CaM play a crucial role in cardiac excitation-contraction 
coupling. Ample evidence has been provided that the entry of acti-
vator Ca2+ through the L-type Ca2+ channel is regulated by CaM 
and CaMKII, which may thereby regulate SR Ca2+ release (4, 23, 
24). It has also been shown that RyR2 is inhibited by CaM in vitro 
(25) and phosphorylated by CaMKII (5, 26, 27). The physiological 
importance of a direct interaction between RyR2 and CaM in car-
diac muscle, however, has remained unclear. Herein we describe a 
genetically modified mouse that has mutations in the CaM-binding 
domain of RyR2. The high specificity of our approach enabled us 
to specifically ascribe the functional changes to only 1 of the mul-
tiple roles of CaM in cardiac excitation-contraction coupling. The 
results show that impaired regulation of the RyR2 ion channel by 
CaM is associated with cardiac hypertrophy, which led to the early 
death of the homozygous mutant mice. However, we were unable to 
determine the exact cause of death because due to the age of mice it 
was not possible to continuously monitor electrocardiograms.
Cardiac hypertrophy is a complex process involving multiple 
signaling pathways (20, 28). The results of our studies add to a 
growing body of work indicating that an aberrant SR Ca2+ release 
is one of the mechanisms leading to cardiac hypertrophy and heart 
failure. Other studies have shown that protein kinase A–mediated 
hyperphosphorylation of the cardiac RyR contributes to impaired 
SR and contractile function during heart failure (5). Overexpression 
Figure 6
Effects of CaM on single WT and homozygous mutant single-
channel activities. Membranes isolated from hearts of 7- to 
10-day-old Ryr2+/+ and Ryr2ADA/ADA mice were fused with lipid 
bilayer. Single-channel currents (downward deflections from 
closed levels [c--]) were recorded at –20 mV in the presence 
of 0.4 μM (A) and 2 μM (B) cis (cytosolic) Ca2+ as described 
in Supplemental Methods in the absence of CaM (top traces) 
and following the addition of 50 nM (middle traces) and 1 μM 
(bottom traces) cis CaM. Bottom panels show mean open-
channel probabilities ± SEM of 4–7 channel recordings, 
normalized to control. *P < 0.05 compared with control (no 
CaM added), determined using Student’s t test. Mean chan-
nel parameters at 2 μM cis (cytosolic) Ca2+ in absence of 
CaM (control) were as follows for WT and mutant channels, 
respectively: open-channel probability (Po), 0.45 ± 0.06 and 
0.35 ± 0.14; events per minute, 4909 ± 1997 and 8721 ± 3797; 
mean open time (To), 7.3 ± 2.5 and 3.4 ± 1.6 ms; mean close 
time (Tc), 14.9 ± 6.2 and 11.3 ± 7.3 ms. Channel parameters 
were calculated from 3 and 4 recordings, respectively, that 
contained only single-channel activity.
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of the SR lumenal Ca2+ binding protein calsequestrin in cardiomyo-
cytes increased SR Ca2+ levels, impaired SR Ca2+ release, and was 
associated with cardiac myopathy (29–31). Constitutively elevated 
levels of CaM (32) and CaMKII (33) in the hearts of mutant mice 
resulted in cardiac hypertrophy, presumably by affecting multiple 
mechanisms including SR Ca2+ release and sequestration. We found 
that class II HDAC/MEF2 signaling was enhanced in homozygous 
hearts at day 1, and we considered the possibility that an altered SR 
Ca2+ release increased CaMKII activity and HDAC phosphorylation 
in 1-day-old homozygous mice, which already 
showed a hypertrophic response. However, our 
data suggest that other kinases that have yet to 
be identified have a major role in upregulating 
HDAC4/MEF2 signaling in Ryr2ADA/ADA mice. 
Calcineurin is another Ca2+-dependent signaling 
molecule implicated in cardiac hypertrophy (20, 
28). Increased mRNA levels of MCIP1 at days 7 
and 10 suggest that calcineurin signaling pathway 
is also involved in cardiac hypertrophy of homo-
zygous mice. However, we observed no change in 
MCIP1 expression at day 1, which suggests that 
changes in calcineurin signaling may be second-
ary to those in HDAC/MEF2 signaling. A more 
detailed determination of the role of calcineurin 
is currently underway in which we cross-breed our 
mutant mice with calcineurin-deficient mice.
RyR2 has a single CaM-binding domain (amino 
acid residues 3583–3603) that is shared by Ca2+-
free and Ca2+-bound forms of CaM (10). In the present 
study, we attenuated the regulation of RyR2 by CaM by 
preparing gene-targeted mice with 3 amino acid substi-
tutions (RyR2ADA) in the CaM-binding domain. We char-
acterized the RyR2 mutant channels in [3H]ryanodine 
binding and single-channel measurements and found 
that homozygous expression of RyR2ADA greatly reduced 
the efficacy of CaM inhibition of RyR2. In contrast, CaM 
inhibition of [3H]ryanodine binding was maintained in 
membranes isolated from heterozygous mice. These 
data are in agreement with our finding that homozy-
gous but not heterozygous mice exhibited a severe form 
of cardiac hypertrophy. Heterozygous mice predomi-
nantly express heterotetrameric channels containing 1, 2, or 3 WT 
subunits. Only a small fraction are homotetrameric WT or mutant 
channels (6.25% each), which assumes a random distribution of 
the 4 subunits in RyR2. Previous [3H]ryanodine binding data (34) 
and our lipid bilayer recordings with channels from heterozygous 
mice support the hypothesis that 1 or 2 WT subunits in tetrameric 
RyR2 mutant channels are sufficient for CaM inhibition.
WT and heterozygous mice also showed no major differences 
with regard to cardiac function or the transcription levels of 3 
Figure 7
Ca2+ imaging of cardiomyocytes from WT and mutant 
hearts. (A–C) Ca2+ transients in cultured neonatal cardio-
myocytes were measured with Ca2+ indicator dye fluo-4 and 
confocal line scanning microscopy as described in Methods. 
Representative traces of Ca2+ transients in WT and homo-
zygous cardiomyocytes are shown. Bars indicate sustained 
time of peak areas for Ca2+ transients. (D) Sustained time of 
peak values of Ca2+ transients of cardiomyocytes (Bars in A 
and B). (E) Half-maximal times (t1/2) of Ca2+ removal by car-
diomyocytes that showed only 1 Ca2+ release event before 
declining to Ca2+ resting level. (F) Resting Ca2+ levels were 
measured with Fura-2 using 340-nm and 380-nm excitation 
wavelengths. Ratio of F340 to F380 is shown. (G) SR Ca2+ 
release induced by addition of 6.3 mM caffeine was mea-
sured using fluo-4. ΔF/Fo, difference in peak and baeline 
fluorescence divided by baseline fluorescence. Data are the 
mean ± SEM of number of experiments shown in parenthe-
ses over each bar. *P < 0.01 compared with WT.
Figure 8
Activities of HDAC kinase and MEF2 in WT and homozygous hearts. (A and B) GST-
HDAC4 fusion proteins were used as a substrate to measure kinase activities of lysates 
from 1-day hearts. (A) [32P] incorporation (top) and Coomassie brilliant blue staining 
(CBBR; bottom) of GST-HDAC4 or GST-HDAC4 with R601F mutation. (B) [32P] radioac-
tivity in GST-HDAC4 SDS-PAGE gel bands was quantified by liquid scintillation counting. 
(C) MEF2 activities of nuclear fractions from 1-day WT and homozygous hearts. Data are 
mean ± SEM of 5–6 experiments. *P < 0.05 compared with WT.
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genes associated with cardiac hypertrophy. Moreover, 13-week-old 
heterozygous mice had heart weight to body weight ratios iden-
tical to those of WT mice. Thus, a small fraction of homotetra-
meric mutant RyR2 channels impaired in their regulation by CaM, 
if present in heterozygous mice (see above), was not sufficient to 
lead to the development of cardiac hypertrophy. On the other 
hand, an impaired CaM regulation of RyR2 caused severe cardiac 
hypertrophy and early death of the homozygous mutant mice. 
In support of the hypothesis of an early hypertrophic response, 
we observed an increased heart weight to body weight ratio and 
upregulation of genes associated with cardiac hypertrophy in mice 
as early as 1 day after birth. Greater differences in these parameters 
were observed in 7- and 10-day-old mice. Biochemical analysis of 
membrane fractions indicated a moderately (but not significantly) 
decreased RyR2 level and reduced SR Ca2+ uptake activity in hearts 
of 1-day-old mice and more pronounced (P < 0.01) reduction in SR 
function in hearts of 7-day-old (RyR2 level) and 10-day-old mice 
(RyR2 level and SR Ca2+ uptake activity). Echocardiography and 
electrocardiography extended these data to intact hearts. Heart 
rates of homozygous mice were significantly slower than those 
of WT mice in both measurements. Echocardiography showed a 
greatly decreased cardiac function in 7- and 10-day homozygous 
hearts as compared with WT hearts.
During an action potential, Ca2+ entering the cell via the L-type 
Ca2+ channel triggers the release of large amounts of Ca2+ from the 
SR by opening Ca2+-gated RyR2 channels. However, the termina-
tion of release of Ca2+ from the SR has remained one of the least 
understood steps in cardiac excitation-contraction coupling. While 
a number of mechanisms have been proposed, none has been fully 
accepted (35). Mechanisms proposed include time-dependent 
Ca2+-induced inactivation of RyR2 (36), depletion of SR Ca2+ (37), 
and the simultaneous closing of all active RyRs in a release unit to 
reduce the Ca2+ concentration to a subthreshold activation level (38, 
39). Previously, we suggested that CaM may have a role in the ter-
mination of SR Ca2+ release, based on our observation that, at Ca2+ 
concentrations of less than 10 μM, CaM increased the duration of 
the close times of single RyR2 channels incorporated into an arti-
ficial bilayer (11). Longer channel closings allow Ca2+ more time to 
diffuse away from the release sites, thereby reducing the probability 
of channel reopening. The present results, demonstrating that an 
impaired CaM regulation of RyR2 results in sustained Ca2+ tran-
sients in cardiomyocytes isolated from homozygous mice supports 
this idea. An intriguing finding was that heterozygous and homo-
zygous cardiomyocytes often exhibited repeated periods of incom-
plete Ca2+ uptake followed by another Ca2+ release episode before 
declining to the resting level. Evidently, RyR2 channels reopened 
before Ca2+ concentrations declined sufficiently to eliminate chan-
nel reopening. Possible explanations include decreased SERCA2a 
activity and/or repeated membrane depolarization, resulting in the 
repetitive activation of L-type Ca2+ and RyR2 channels. Changes 
in resting Ca2+ levels and SR Ca2+ store size did not appear to con-
tribute to abnormal Ca2+ release in Ryr2ADA/ADA cardiomyocytes, as 
both were not significantly different between the 3 groups of car-
diomyocytes. We caution, however, that due to the early death of 
the homozygous mutant mice these studies were done with cardio-
myocytes isolated from the hearts of 1-day-old mice. Their culture 
for 7–13 days might have resulted in gene regulation different from 
that found in intact hearts. Ca2+ transients in the hearts of 7- to 
10-day-old homozygous mice are most likely less severely altered 
than in isolated cardiomyocytes and remain to be determined.
Several mutations of RyR2 in humans have been reported to cause 
catecholaminergic polymorphic ventricular tachycardia (CPVT) and 
arrhythmogenic right ventricular cardiomyopathy (40). A deficiency 
in SR lumenal cardiac calsequestrin in humans (41) and mice (42) 
as well as a missense mutation (D307H) (43) also caused CPVT. 
These mutations result in imbalance of Ca2+ handling (40, 42, 44). 
Although an impaired regulation of RyR2 by CaM has not been 
demonstrated in human cardiomyopathies, our genetically modi-
fied mice provide a promising model that should be helpful to inves-
tigators studying cardiac hypertrophy and heart failure in humans.
Methods
Materials. [3H]ryanodine was obtained from PerkinElmer, Tran35S-label 
from ICN Radiochemicals, unlabeled ryanodine from EMD Biosciences, 
Complete protease inhibitors from Roche Applied Science, and phospho-
lipids from Avanti Polar Lipids Inc. Unlabeled CaM and [35S]CaM were 
prepared as previously described (34). Unless otherwise specified, all other 
chemicals were obtained from Sigma-Aldrich.
Generation of mice with mutations in CaM-binding domain of RyR2. Ryr2 gene 
was cloned from 129/SvEv mouse genomic DNA library. Multiple base 
changes in exon 75, which encodes the CaM-binding domain, were intro-
duced by pfu polymerase-based chain reaction using mutagenic oligonu-
cleotides and the QuikChange site-directed mutagenesis kit (Stratagene). 
A 6.5-kbp fragment with the ADA mutation and a 1.2-kbp fragment were 
cloned into pBR322 (New England Biolabs) containing neomycin-resistant 
gene flanked by loxP sequences and thymidine kinase gene (Supplemen-
tal Figure 3). Mutant mice carrying the ADA mutation were prepared as 
described in Supplemental Methods.
The mice were handled following the NIH guidelines for the use and 
care of experimental animals. All experiments were approved by the Insti-
tutional Animal Care and Use Committee of the University of North Caro-
lina at Chapel Hill.
Morphological analysis. Mouse hearts at 10 days of age were fixed with 4% 
(w/v) paraformaldehyde in PBS (pH 7.4) and dehydrated by increasing con-
centrations of ethanol in water. Paraffin sections (5 μm in thickness) of 
tissues were cut and stained with H&E and Masson trichrome. To visualize 
cell membranes of cross-sectioned cardiomyocytes, paraffin-free heart sec-
tions were incubated with 50 μg/ml TRITC-conjugated wheat germ agglu-
tinin in PBS for 1 hour and then washed 3 times with PBS. TRITC fluores-
cence images were captured and cell cross-sectional areas were calculated 
using ImageJ software (version 1.34s; http://rsb.info.nih.gov/ij/).
Quantitative RT-PCR. Gene expression was measured by quantitative RT-
PCR using the ABI Prism 7700 Sequence Detector (Applied Biosystems). 
RNA was isolated from left and right ventricles of 1-day-old mice and left 
ventricle of 7- and 10-day-old mice with the ABI Prism 6700 Automated 
Nucleic Acid Workstation according to the manufacturer’s protocol. Prim-
ers and the corresponding fluorogenic probes for β-myosin heavy chain, 
atrial natriuretic peptide, brain natriuretic peptide, and β-actin genes were 
as previously described (45). Forward and reverse primers for RyR2 were 
5′-CTGTCCCTGAGGTACAAGAA-3′ and 5′-AGCTTTCTCTGGTTCC-
GACT-3′, respectively. Fluorogenic probe was FaM-5′-TTCAGGGAG-
CAGAAGGCGAAAGAGGA-3′-TAMRA. Forward and reverse primers and 
probe for MCIP1 were 5′-CCCCGTCATAAATTACGATCT-3′, 5′-ACACT-
GGGAGTGGTGTCTGT-3′, and 5′-FaM-AGTTCATACTTCTCTCCTG-
GCCCCA-TAMRA-3′, respectively. Relative levels of gene expression as a 
percentage of WT were determined for each gene with β-actin as reference.
Echocardiography and electrocardiography. To determine left ventricular 
cardiac function, transthoracic M-mode echocardiography was per-
formed on restrained and unanesthetized 7- and 10-day-old mice using 
Vevo 660 high-resolution imaging system (VisualSonics). Electrocardio-
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grams were performed on restrained, unanesthetized 10-day-old mice 
using mouse pad with 4 electrodes connected to electronic control mod-
ule (THM100; Indus Instruments).
Preparation of membrane fractions. Hearts were homogenized in 20 mM 
imidazole, pH 7.0, 0.3 M sucrose, 150 mM NaCl, 0.1 mM EGTA, and 
protease inhibitors (Complete; Roche Applied Science; 1 mM glutathione, 
oxidized form) with a Tekmar Tissumizer for twice for 5 seconds each time 
at a setting of 13,500 rpm. Homogenates were centrifuged for 45 minutes 
at 100,000 g in a Type 75Ti rotor (Beckman), and pellets were resuspended 
in the above buffer without EGTA and glutathione to obtain a crude mem-
brane fraction. Membranes were stored in small aliquots at –135°C.
Single-channel analysis. Single-channel measurements of WT and mutant 
RyR2s were performed in planar lipid bilayers as described in ref. 46 and 
Supplemental Methods.
[3H]ryanodine binding. Ryanodine binds with high specificity to RyRs and 
is widely used as a probe of channel activity because of its preferential bind-
ing to the open-channel state (15). [3H]ryanodine binding experiments 
were performed with crude membrane fractions from hearts, as described 
in Supplemental Methods.
CaM-Sepharose pull-down assay. Membrane fractions of mouse hearts were 
solubilized in 40 mM NaPIPES, pH 7.4, 1 M NaCl, 5 mM DTT, 0.1 mM 
EGTA, 2.5% Triton X-100, and protease inhibitors. After eliminating the 
insoluble fractions by centrifuge, supernatant was diluted with 7 volumes of 
H2O and then incubated with CaM-Sepharose (GE HealthCare) for 20 hours 
at 4°C in the presence of 900 μM Ca2+. After washing the CaM-Sepharose, 
bound RyR2s were eluted and analyzed by Western blot.
45Ca2+ uptake. ATP-dependent 45Ca2+ uptake by crude membrane fractions 
was determined using a filtration method. 45Ca2+ uptake was initiated by 
placing membranes in 0.15 M KCl; 20 mM imidazole, pH 7.0; solution 
containing 5 mM ATP, 8 mM Mg2+, and 5 mM potassium oxalate (a Ca2+ 
precipitating agent to increase Ca2+ uptake capacity; ref. 47); 10 μM ruthe-
nium red (to inhibit RyRs; ref. 48); 5 mM NaN3 (to inhibit mitochondrial 
Ca2+ uptake); 1 mM EGTA; and Ca2+ and 45Ca2+ to yield a free Ca2+ concen-
tration of 0.5 μM. To obtain 45Ca2+ uptake rates, aliquots were placed at 2.5, 
5, and 10 minutes on 0.45 μM Millipore filters under vacuum and rinsed 
with three 3-ml volumes of ice-cold (°0) solution containing 0.175 M KCl, 
5 mM imidazole, pH 7.0. Radioactivity remaining with the vesicles on the 
filters was determined by liquid scintillation counting.
Intracellular Ca2+ imaging. Neonatal cardiomyocytes were prepared from 
the ventricular muscle of mice approximately 1 day old using Neonatal 
Cardiomyocyte Isolation System (Worthington Biochemical Corp.) accord-
ing to the manufacturer’s protocol. Cells were maintained for 7–13 days 
in M199 medium with 10% fetal bovine serum at 37°C with 5% CO2. 
Intracellular Ca2+ transients were recorded using fluorescent Ca2+ indicator 
dye fluo-4, AM, (Invitrogen) and confocal laser scanning microscopy (Zeiss 
LSM 510). Cells were incubated with 5 μM fluo-4, AM, in culture media at 
37°C with 5 % CO2. After loading for 30 minutes, cells were rinsed with 
L15 media containing 10% fetal bovine serum and 15 mM NaHEPES, pH 
7.3, to remove nonhydrolyzed fluorophore. Spontaneously beating cells 
were defined as regions of interest, and fluorescence changes of line image 
excited by 488-nm argon laser as a function of time were measured through 
505-nm long-pass filter at room temperature.
Resting Ca2+ levels of cardiomyocytes were monitored with Fura-2 and 
inverted microscope (Nikon TE2000-U) with high-sensitivity charge-cou-
pled device camera (DVC1412; Digital Video Camera Co.). Cardiomyocytes 
were loaded with 5 μM Fura-2 (AM) (TEF Labs) as described above and 
excited alternatively at 340 nm and 380 nm. The fluorescence emissions of 
spontaneous beating cells were collected through 470–550 nm band-pass 
filter. To compare the resting Ca2+ level of experimental groups, the ratio of 
emission signals at 340 nm and 380 nm excitation was calculated.
Caffeine-induced Ca2+ release was measured with fluo-4 and the inverted 
microscope system. Fluorescence changes of cytoplasm in response to addi-
tion of 6.3 mM caffeine were collected through 515- to 555-nm band-pass 
filter. Excitation wavelength range was from 483 nm to 495 nm.
Measurement of CaMKII, HDAC kinases, and MEF2. CaMKII activities were 
measured using SignaTECT Calcium/Calmodulin-dependent Protein 
Kinase Assay System (Promega). Briefly, hearts were homogenized in 20 
mM Tris-HCl, pH 8.0, 2 mM EGTA and 2 mM EDTA, 2 mM DTT, protease 
inhibitors (Complete; Roche Applied Science) and phosphatase inhibitors 
(Sigma-Aldrich) with a Tekmar Tissumizer twice for 5 seconds each time at 
a setting of 13,500 rpm. Homogenates were centrifuged for 10 minutes at 
350 g to obtain a supernatant fraction that was assayed for CaMKII activity 
according to the manufacturer’s instructions.
HDAC kinase activities were determined as previously described (19). 
Briefly, heart lysates (prepared in 20 mM Tris [pH 7.4], 150 mM NaCl, 0.6% 
NP-40, and protease inhibitors) were incubated with glutathione-S-trans-
ferase–HDAC4 fusion proteins (amino acids 419–670) for 4 hours at 4°C. 
After washing with lysis buffer, beads were resuspended in kinase reaction 
buffer (25 mM HEPES [pH 7.6], 10 mM MgCl2, 0.1 mM CaCl2, 12.5 μM 
ATP, and 5 μCi [γ-32P]ATP), and reactions were performed for 30 minutes at 
room temperature. Proteins were resolved in SDS-PAGE, and [32P] radioac-
tivity was analyzed by phosphoimager and liquid scintillation counting.
MEF2 activation was measured using Active Motif TransAM MEF2 kit 
according to the manufacturer’s instructions.
Biochemical assays and data analyses. Western blot analysis and a standard 
curve prepared with purified CaM were used to determine total CaM con-
centrations in the hearts of the 3 genotypes. Free Ca2+ concentrations were 
obtained by including in solutions the appropriate amounts of Ca2+ and 
EGTA as determined using the stability constants and the computing 
method described in ref. 49. Free Ca2+ concentrations of 1 μM or more 
were verified with the use of a Ca2+ selective electrode.
Results are given as mean ± SEM. The 3 genotypes were compared by 
1-way ANOVA followed by Tukey’s procedure. Where indicated, differences 
were analyzed using 2-tailed Student’s t test.
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